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Abstract: AIMS Breast adenomyoepitheliomas (AMEs) are uncommon tumors. Most estrogen receptor
(ER)-positive AMEs have mutations in PI3K pathway genes, whereas ER-negative AMEs usually harbor
concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we sought to
determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) analysis for detection
of HRAS Q61R mutations in AMEs. METHODS AND RESULTS 26 AME (14 ER-positive, 12 ER-
negative) previously subjected to massively parallel sequencing (n=21) or Sanger sequencing (n=5) of
the HRAS Q61 hotspot locus were included in this study. All AMEs were subjected to IHC using a
monoclonal (SP174) RAS Q61R-specific antibody, in addition to detailed histopathologic analysis. Nine
ER-negative AMEs harbored HRAS mutations, including Q61R (n=7) and Q61K (n=2) mutations.
5/7 (71%) AMEs with HRAS Q61R mutations were positive by IHC, whereas none of the AMEs lacking
HRAS Q61R mutations (n=17) were immunoreactive. RAS Q61R immunoreactivity was restricted to the
myoepithelium in 80% (4/5) of cases, whereas one case displayed immunoreactivity in both the epithelial
and myoepithelial components. RAS Q61R IHC-positive AMEs were associated with infiltrative borders
(P<0.001), necrosis (P<0.01) and mitotic index in the epithelial (P<0.05) and myoepithelial (P<0.01)
components. RAS Q61R IHC assessment did not detect Q61K mutations (0/2). CONCLUSIONS IHC
analysis of RAS Q61R displays a high specificity (100%) and moderate sensitivity (71%) for detection
of HRAS Q61R mutations in breast AMEs, and appears not to detect HRAS Q61K mutations. IHC
analysis of RAS Q61R may constitute a useful marker in the diagnostic workup of ER-negative AMEs.
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ABSTRACT 
Aims: Breast adenomyoepitheliomas (AMEs) are uncommon tumors. Most estrogen receptor 
(ER)-positive AMEs have mutations in PI3K pathway genes, whereas ER-negative AMEs usually 
harbor concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we 
sought to determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) 
analysis for detection of HRAS Q61R mutations in AMEs.
Methods and results: 26 AME (14 ER-positive, 12 ER-negative) previously subjected to 
massively parallel sequencing (n=21) or Sanger sequencing (n=5) of the HRAS Q61 hotspot 
locus were included in this study. All AMEs were subjected to IHC using a monoclonal (SP174) 
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AMEs harbored HRAS mutations, including Q61R (n=7) and Q61K (n=2) mutations. 5/7 (71%) 
AMEs with HRAS Q61R mutations were positive by IHC, whereas none of the AMEs lacking 
HRAS Q61R mutations (n=17) were immunoreactive. RAS Q61R immunoreactivity was restricted 
to the myoepithelium in 80% (4/5) of cases, whereas one case displayed immunoreactivity in both 
the epithelial and myoepithelial components. RAS Q61R IHC-positive AMEs were associated with 
infiltrative borders (P<0.001), necrosis (P<0.01) and mitotic index in the epithelial (P<0.05) and 
myoepithelial (P<0.01) components. RAS Q61R IHC assessment did not detect Q61K mutations 
(0/2).
Conclusions: IHC analysis of RAS Q61R displays a high specificity (100%) and moderate 
sensitivity (71%) for detection of HRAS Q61R mutations in breast AMEs, and appears not to 
detect HRAS Q61K mutations. IHC analysis of RAS Q61R may constitute a useful marker in the 
diagnostic workup of ER-negative AMEs.
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INTRODUCTION
Breast adenomyoepitheliomas (AMEs) are a heterogeneous group of lesions with dual epithelial 
and myoepithelial cell differentiation, classically composed of glandular epithelial structures 
surrounded by myoepithelial cell proliferation1-3. Whilst most lesions are benign, a spectrum of 
lesions pertaining to this category has been described, ranging from purely benign to frankly 
malignant2, 4-6. Moreover, a subset of AMEs display overlapping morphology and 
immunophenotype with other lesions. At one end of the spectrum AMEs overlap with intraductal 
papillomas with myoepithelial cell hyperplasia, whereas, in the other end of the spectrum, 
malignant AME can mimic metaplastic breast carcinoma or what is so called malignant 
myoepithelial carcinoma7-10, rendering a definite diagnosis of AME difficult to formulate at times11. 
The World Health Organization (WHO) guidelines describe malignant forms of AME and some 
cases were reported in the literature5, 8, but clear criteria to distinguish this entity from the spindle 
cell metaplastic carcinoma apart from identification of benign AME component in the tumor 
remain to be defined1, 2. It is also our observation (EAR) that in a proportion of cases the 
concordance between morphology and immunoprofile of myoepithelial and epithelial cell 
components is low, making an accurate diagnosis and the distinction of each component a 
challenging task in such cases. The latter feature is important in cases showing atypia as the 
criteria for defining atypia are different between epithelial and myoepithelial cell components. 
Lack of definite diagnostic and molecular features of AME with their ambiguous nature and 
histogenesis leads to challenges in patients’ management and outcome prediction.    
The repertoire of genetic alterations affecting breast cancers has now been well-characterized, 
and includes recurrent mutations affecting TP53, PIK3CA, PTEN and GATA312-14. In the large 
pool of breast carcinomas, and other rare tumors that originate in the breast, not uncommonly 
carry highly recurrent somatic genes alterations15, 16. We have recently shown that AMEs are 
underpinned by characteristic genetic alterations, which vary according to their estrogen receptor 
(ER) status17. ER-positive AMEs are associated with mutually exclusive PIK3CA or AKT1 hotspot 
mutations, whereas up to 60% of ER-negative AMEs harbor concurrent HRAS Q61 hotspot 
mutations and mutations affecting either PIK3CA or PIK3R117. Based on the results of this study17 
and a comparison with the repertoire of somatic mutations in common forms of breast cancer by 
The Cancer Genome Atlas12 and The International Cancer Genome Consortium14, we concluded 
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their presence in conjunction with PI3K-AKT pathway activation likely constitutes the driver 
genetic events in the development of AME.
There is an increasing interest in the application of immunohistochemistry (IHC) for the detection 
of specific hotspot mutations, particularly those that could be targetable, such as for instance 
BRAF V600E mutations18 in melanoma19,  colorectal carcinoma20 and papillary thyroid 
carcinoma21, among others.
In this study we sought to determine the sensitivity and specificity of RAS Q61R 
immunohistochemical analysis for the detection of previously confirmed HRAS Q61R mutations in 
a series of AMEs. We also investigated whether specific histologic differences between RAS 
Q61R IHC-positive and –negative AMEs can be identified.
MATERIALS AND METHODS
Cases and DNA sequencing data
In this study, we included 26 breast AMEs with available material from the work by Geyer et al17. 
Representative histologic formalin-fixed paraffin-embedded (FFPE) blocks of breast AMEs 
included in this study were retrieved from the author’s institutions. Approvals by the IRB and the 
local research committees have been obtained, and patient consent was obtained in accordance 
to the approved protocols. All cases were centrally reviewed by five pathologists with expertise in 
breast pathology (FCG, ME, IOE, and EAR and JSRF) for diagnosis confirmation following the 
WHO criteria1. Assessment of various histologic characteristics was conducted by three 
pathologists (FP, FCG and APMS), including growth pattern (tubular or papillary), tumor border 
(encapsulated, multinodular or infiltrative), epithelial and myoepithelial nuclear grade, which was 
evaluated following the Nottingham grading system of breast cancer22, epithelial and 
myoepithelial mitotic rate, defined as the number of mitotic figures per mm2, and presence or 
absence of necrosis. Whole-exome sequencing (n=9), MSK Integrated Mutation Profiling of 
Actionable Cancer Targets (MSK-IMPACT)23 targeted sequencing (n=12) and Sanger sequencing 
(n=5) data for the assessment of the mutational status of HRAS Q61 hotspot locus were retrieved 
from Geyer et al17. Immunohistochemical staining for p63 and ER were conducted in the study by 
Geyer et al24. ER status was assessed by IHC following the American Society of Clinical 
Oncology/ College of American Pathologists (ASCO/CAP) guidelines25, using 1% of positive 
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Sanger sequencing
Areas with overgrowth of epithelial or myoepithelial cells of three AMEs were selected based on 
p63 expression and morphology. The epithelium and myoepithelium of only the selected areas 
was separately microdissected from eight micron-thick FFPE histological sections under a 
stereomicroscope (Olympus SZ61), following careful histologic review and use of the 
corresponding p63 IHC stains to highlight the myoepithelium, as reference. DNA was extracted 
using the DNAeasy Blood and Tissue Kit (Qiagen), following manufacturers’ instructions. The 
presence of mutations affecting the HRAS Q61 hotspot locus was assessed by Sanger 
sequencing. In brief, PCR amplification was conducted using AmpliTaq Gold 360 Master Mix Kit 
(Life Technologies), as previously described16. Following purification with exoSAP-IT, PCR 
products were subjected to Sanger sequencing using previously validated primers17 
encompassing the HRAS Q61 hotspot locus (Supplementary Table 1). Sequence 
electropherograms corresponding to the forward and reverse strands were manually analyzed.
Immunohistochemistry
Immunohistochemical analysis was conducted using the monoclonal antibody SP174 (ab227658; 
Abcam, Cambridge, MA), an antibody generated against Q61R mutant NRAS, that also 
recognizes Q61R mutant HRAS and KRAS27 due to the homology of the various RAS proteins28. 
The analyses were performed on a Leica Bond-3 automated stainer platform (Leica, Buffalo 
Grove, IL). In brief, 4-μm-thick deparaffinized FFPE tissue sections were incubated with primary 
antibody at 1:100 preceded by a heat-based antigen retrieval step employing a high pH buffer 
solution (ER2, Leica). As a secondary reagent, a polymeric kit (Refine, Leica) was employed. 
Appropriate positive and negative controls were included in each run. The evaluation of the IHC 
expression of mutant RAS Q61R was performed by three pathologists (FP, FCG and APMS) 
blinded to the results of the sequencing analysis. 
Statistical analysis
Statistical analyses were performed using R v3.1.2. Fisher’s exact test was used for comparisons 
between categorical variables. All tests were two-sided and P-values<0.05 were considered 
statistically significant.
RESULTS
Our study included 26 AMEs previously reported in our study by Geyer et al17, of which 12 were 
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subjected to WES or MSK-IMPACT sequencing, respectively.17 In addition, the presence of 
mutations affecting the HRAS Q61 hotspot locus had been previously interrogated using Sanger 
sequencing in five AMEs (Supplementary Table 2).17 Seventy-five percent (9/12) of the ER-
negative AMEs harbored HRAS Q61 hotspot mutations, including Q61R (n=7) and Q61K (n=2) 
mutations (Fig. 1). None of the ER-positive AMEs (n=14) were found to harbor HRAS Q61 
hotspot mutations (Fig 1). 
We sought to determine whether HRAS Q61R mutations could be detected by IHC. We subjected 
all 26 cases to immunohistochemical analysis with an antibody that detects Q61R mutant RAS 
(i.e. mutant NRAS, KRAS or HRAS)27. Seventy-one percent (5/7) of AMEs harboring HRAS 
Q61R mutations were immunoreactive using these antibodies, showing diffuse cytoplasmic 
and/or membranous staining, as previously reported in different tumor types29, 30, and consistent 
with the reported localization of Ras isoforms in the plasma membranes and cytoplasmic 
organelles31-33  (Fig. 1 and Fig. 2A-2D). Notably, the two AMEs harboring HRAS Q61K mutations 
were negative by IHC (Fig.1). None of the 17 HRAS wild-type AMEs included in this study 
displayed immunoreactivity by IHC (Fig. 1 and Fig. 2E-2F). RAS Q61R immunoreactivity was 
found to be restricted to the myoepithelial component in four cases (Fig. 2A-2B) and present in 
both the epithelial and myoepithelial component in one case (AM52; Fig 2C-2D). Taken together, 
these findings show that the immunohistochemical detection of HRAS Q61R mutations in ER-
negative breast AMEs is moderately sensitive (71%) and highly specific (100%), whereas in ER-
positive AMEs, this antibody was of limited use as no cases were found to harbor HRAS Q61 
hotspot mutations and/or RAS Q61R protein expression.
We next sought to determine whether HRAS Q61R hotspot mutations would be present in the 
epithelium and myoepithelium of AMEs, or if they would be restricted to either histologic 
component. We conducted Sanger sequencing analysis of the HRAS Q61 hotspot locus in the 
separately microdissected epithelial and myoepithelial components of cases with available 
material (AM32, AM48 and AM52). Our analysis revealed the presence of HRAS Q61R hotspot 
mutations in both, epithelial and myoepithelial components of all three adenomyoeptiheliomas 
assessed (Figure 3A-3F). These findings support the notion that both the epithelium and 
myoepithelium of adenomyoepitheliomas are neoplastic.
RAS Q61R IHC-positive AMEs, compared to IHC-negative cases, more frequently displayed 
infiltrative tumor borders (100% vs 9.5%; P<0.001; Table 1 and Fig. 4A), association with 
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mitotic index (Table 1 and Fig. 4C-4D). All of the RAS Q61R IHC-positive AMEs were ER-
negative (Table 1 and Fig. 4E-4F), whereas the majority (67%) of RAS Q61R IHC-negative 
AMEs were ER-positive (P<0.05; Table 1). We observed no association of immunoreactivity for 
RAS Q61R with growth pattern or epithelial or myoepithelial nuclear grade (P>0.05; Table 1).
DISCUSSION
Here we evaluated the sensitivity and specificity of IHC analysis for the detection of mutated RAS 
Q61R protein in a set of 26 previous sequenced AMEs17, encompassing 14 ER-positive AMEs 
and 12 ER-negative AMEs; of the 12 ER-negative AMEs, nine harbored mutations affecting the 
HRAS Q61 hotspot locus. Our findings show that IHC analysis has a high specificity and 
moderate sensitivity for identifying HRAS Q61R-mutated AMEs among ER-negative cases. The 2 
cases Q61K HRAS-mutated cases, however, were not detected by IHC in this series. IHC 
evaluation showed no immunoreactivity in any of the 14 ER-positive AMEs, which lacked HRAS 
mutations providing further support to the remarkable specificity of IHC evaluation for the 
detection of Q61R HRAS mutations. Interestingly, RAS Q61R immunoreactivity was observed to 
be restricted to the myoepithelial component in four cases, and present in both the epithelial and 
myoepithelial components in one case. Nonetheless, our Sanger sequencing analyses of 
separately microdissected epithelium and myoepithelium of three AMEs revealed the presence of 
HRAS Q61R mutations in both histologic components. These findings are in agreement with our 
previous observations showing that HRAS Q61R mutations identified in ER-negative AMEs were 
clonal.17 Hence, it is possible that the epithelial component of a subset of cases expressed a 
mutant HRAS Q61R, but at levels not detectable by immunohistochemistry. The molecular 
mechanisms underpinning the differences in expression and/ or immunohistochemical detection 
of HRAS Q61R mutations in the epithelium and myoepithelium of AMEs warrant further study.
Breast AMEs are a specific group of tumors both within the large pool of breast lesions, and 
within the wide spectrum of myoepithelial lesions34. Though not all AMEs show HRAS mutations 
and most of them are either negative or weakly positive for ER receptors10, a strong correlation 
between HRAS mutation and the ER-negative subgroup has been previously reported by our 
group17. In our study, out of 12 ER-negative AMEs, 9 harbored HRAS mutations affecting the Q61 
hotspot locus, whereas the remaining 3 were wild-type for HRAS. We have also recently 
observed, that a subset of AMEs lacking HRAS mutations, might be underpinned by HMGA2 
rearrangements, suggesting that a subset of AMEs could be related to salivary gland pleomorphic 
adenomas35. The relevance of the genetic alterations underpinning AMEs is of practical 
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from other ER-negative breast tumors, including metaplastic carcinomas, adenoid cystic 
carcinomas and pleomorphic adenomas, with which adenomyoepitheliomas may show 
morphologic overlap36. The detection of HRAS Q61R mutations in AMEs with ambiguous 
morphology may help settle such challenging cases. Nonetheless, given that RAS Q61R 
immunohistochemical assessment has a moderate sensitivity for the detection of HRAS Q61R 
mutations and does not detect HRAS Q61K mutations, along with the fact that a subset of 
approximately 30%-40% of ER-negative AMEs lack HRAS mutations17, the diagnosis of AME 
should not be ruled out in cases displaying the typical histologic features but lacking RAS Q61R 
expression by by immunohistochemistry.
Though it is generally considered that triple-negative breast neoplasms are biologically more 
aggressive, this is not the case across the entire spectrum of these tumors37. AMEs are 
considered to be among the least aggressive breast neoplasms and are generally cured by local 
excision alone1. A spectrum of these lesions appears to exist with some AMEs showing 
unpredictable behavior. Nodal metastasis has been reported in AMEs ranging from benign to 
atypical cases with no frank malignant histological features4, 5, 14, 38. There are no established 
criteria on how to catalogue these lesions1, though general features such as mitotic activity, 
necrosis, cellular pleomorphism, peripheral invasive border and overgrowth of myoepithelium are 
suggested2. In our study, out of 7 cases categorized as having an infiltrative border, five AMEs 
were immunoreactive for mutant RAS Q61R. A sixth case with infiltrative borders showed the 
Q61K mutation, making for a total of 6 out of 7 cases with infiltrative border associated with 
HRAS mutations. The presence of necrosis was also recorded in all five cases with IHC positivity 
for RAS Q61R, and compared to IHC-negative AMEs, RAS Q61R IHC-positive cases had a 
higher mitotic index in both the epithelial and myoepithelial components. These findings 
corroborate the more aggressive histologic features associated with lack of ER expression and 
the presence of HRAS Q61 hotspot mutations in AMEs17.
Limitations of the current study include the relatively low number of AMEs harboring HRAS 
mutations and the lack of follow-up information, due to the multi-institutional nature of our cohort. 
Despite these limitations, our study demonstrates that the IHC analysis of HRAS Q61R displays a 
high specificity and moderate sensitivity for the detection of HRAS Q61R mutations in breast 
AMEs, and it appears not to detect HRAS Q61K mutations. Having previously concluded that 
these mutations likely constitute founder genetic events in the development of ER-negative 
AMEs17, detection of immunoreactivity for RAS Q61R mutations would aid in distinguishing these 
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mutations appear to be restricted to ER-negative AMEs, the immunohistochemical assessment of 
HRAS Q61R may represent a useful marker in the diagnostic workup of these lesions.
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Table 1. Clinicopathologic features of the breast adenomyoepitheliomas studied according 
to RAS Q61R immunoreactivity
RAS Q61R IHC





Positive 0.0% (0) 66.7% (14)
ER
Negative 100.0% (5) 33.3% (7)
0.012
Tubular 60.0% (3) 76.2% (16)
Growth pattern
Papillary 40.0% (2) 23.8% (5)
0.5875
Encapsulated 0.0% (0) 23.8% (5)
Multinodular 0.0% (0) 66.7% (14)Tumor border
Infiltrative 100.0% (5) 9.5% (2)
0.0003
Low 0.0% (0) 23.8% (5)
Intermediate 0.0% (0) 38.1% (8)
Nuclear grade  
(epithelium)
High 100.0% (5) 38.1% (8)
0.0816
Low 0.0% (0) 4.8% (1)
Intermediate 20.0% (1) 47.6% (10)
Nuclear grade 
(myoepithelium)
High 80.0% (4) 47.6% (10)
0.467
<=0.8 40.0% (2) 81% (17)
>0.8 but <=2.1 40.0% (2) 19% (4)
Epithelial 
mitoses/ mm2
>2.1 20.0% (1) 0% (0)
0.0494
<=0.8 0.0% (0) 85.7% (18)
>0.8 but <=2.1 60.0% (3) 4.8% (1)
Myoepithelial 
mitoses/ mm2
>2.1 40.0% (2) 9.5% (2)
0.0013
Absent 0.0% (0) 76.2% (16)
Necrosis
Present 100.0% (5) 23.8% (5)
0.0038
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FIGURE LEGENDS
Figure 1. Estrogen receptor-negative breast adenomyoepitheliomas harbor recurrent 
HRAS Q61R hotspot mutations, which are detectable by immunohistochemistry, co-
occurring with mutation in PI3K genes.
Heatmap depicting somatic mutations affecting the HRAS Q61 hotspot locus and 
immunoreactivity for RAS Q61R in the 26 breast adenomyoepitheliomas included in this study. 
Cases are shown in columns and genes in rows. Mutations are color-coded according to the 
legend. Estrogen receptor status and the sequencing platform used are depicted in phenotype 
bars (top). 
Figure 2. Detection of HRAS Q61R hotspot mutations in breast adenomyoepitheliomas by 
immunohistochemistry.
(A-B) Representative micrographs of (A) hematoxylin and eosin-stained (H&E) sections and (B) 
RAS Q61R immunohistochemical expression of AM8 showing immunoreactivity in the 
myoepithelial component. (C-D) Representative micrographs of (C) H&E sections and (D) RAS 
Q61R immunohistochemical expression of AM52 displaying immunoreactivity in both the 
epithelial and myoepithelial component. (E-F) Representative micrographs of (E) H&E stained 
sections and (F) lack of RAS Q61R immunohistochemical expression in AM3. Scale bars, 50 m.
Figure 3. HRAS Q61R mutations are present in the epithelial and myoepithelial 
components of breast adenomyoepitheliomas.
(A-F) Representative micrographs of hematoxylin and eosin-stained (H&E) sections (left), p63 
(center) and RAS Q61R (right) immunohistochemical expression in the epithelial and 
myoepithelial components of adenomyoepitheliomas AM32 (A-B), AM48 (C-D) and AM52 (E-F). 
Representative Sanger electropherograms of the HRAS Q61 hotspot locus of separately 
microdissected epithelial and myoepithelial components of AM32 (epithelium, A; myoepithelium, 
B), AM48 (epithelium, C; myoepithelium, D), and AM52 (epithelium, E; myoepithelium, F).
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Representative micrographs of (A) hematoxylin and eosin-stained (H&E) sections of AM9 
showing infiltrative borders, (B) AM52 displaying areas of necrosis, (C) high epithelial and 
myoepithelial nuclear grade and (D) frequent epithelial and myoepithelial mitotic figures. (E-F) 
Representative micrographs of (E) H&E stained sections and corresponding (F) estrogen 
receptor (ER) immunostain of AM8. Scale bars, (A) 200 m, (B) 100 m, (C-D) 20 m and (E-F) 
50 m.
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